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Abstract
Amgen is shifting certain drugs from traditional vial and syringe primary containers to more patient
friendly delivery devices known as combination products. Combination products are defined by the
combination of a medical device and drug into a single entity. These new products are accompanied by
new regulations and new production processes. Traditional drug manufacturers are required by the FDA
to embrace certain practices traditionally pertinent to medical devices. As Amgen seeks to integrate these
device processes into its business processes, additional quality procedures are necessary to control and
improve the new production processes.
This thesis seeks to examine process control techniques in the clinical manufacturing organization in an
attempt to understand and improve the current new processes. A control plan was developed based on risk
inputs, observational run data, and batch release requirements. A data collection process was then
implemented and data was analyzed in control charts and aggregated defect rate analysis. Results show
that 1) the overall assembly process appeared to stabilize over the period of analysis, 2) although
processes were within specification limits, none of the inspection processes were entirely within statistical
control, and g investigative avenues for out of control processes are suggested as a part of the control
feedback loop. Recommendations regarding managerial challenges in implementing a quality control
system are also suggested.
The opinions expressed herein are solely those of the author and do not necessarily reflect those of
Amgen Inc.
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1 Introduction
One of Amgen's core values is "Ensure Quality." The degree to which Amgen internalizes this value is
fascinating-"quality-mindedness [1]" is pervasive within all levels of the organizations. As Amgen gears
up to introduce an array of patient friendly delivery platforms, Amgen must adjust to a changing
regulatory environment while maintaining the highest standard of product quality. There is a great scope
for achieving high quality levels through the application of statistical process controls. Although the
importance of quality is clear at every level of Amgen, a coherent statistical process control approach is
not widely implemented within the clinical organization.
Amgen is currently engaged in rolling out new types of drug delivery platforms, known as combination
products. These combination products require new manufacturing processes, assembly processes, and
ultimately new quality processes. As Amgen adapts to new combination product regulations, Amgen must
also implement appropriate quality processes to support combination product production. These quality
processes range from high level business procedures (often termed "big Q Quality") to specialized
procedures pertaining to product quality (termed "little q quality").
1.1 General Problem Description
This thesis describes the implementation of process controls to a new final assembly process in the
clinical production environment. The primary hypothesis that this thesis strives to substantiate is as
follows:
Judicious collection and analysis of process data can be a solid basis for assessing
current process health, predicting future process health, and improving process quality.
This thesis will discuss implementation of a control plan, including: the data collection system, methods
of data analysis, and results and conclusions. This thesis also attempts to address the fine line between
excessive quality investment, and effective quality investment, in addition to the creation of a coherent
statistical process control strategy within Amgen's clinical organization. It is important to distinguish that
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this thesis particularly focuses on statistical process control techniques within Amgen's clinical
production organization-a distinctly separate entity with separate procedural requirements from the
commercial production organization.
1.2 General Approach and Results
A control plan was created based on appropriate risk inputs, observational data, and batch release
requirements. This control plan was ultimately implemented and a data collection system has been put in
place. A baseline set of data forms a cohesive platform for setting control limits across the various control
points that are monitored. Ultimately, the work of this thesis is foundational for a continuing quality
control cycle. As the process matures, it is intended for the process to evolve. It is also intended for this
quality control effort to serve as a flagship for inspiring further such efforts within Amgen's clinical
manufacturing organization.
1.3 Thesis Organization
Chapter 1 contains a broad overview of the thesis and its organization.
Chapter 2 contains a background of Amgen and the clinical production group, the FDA's involvement in
regulation, and the definition and intent of combination products.
Chapter 3 describes the current state of process control within Amgen and the background and details of
the Identify, Track, and Control Variation (ITCV) process control program.
Chapter 4 is a literature review discussion accepted control methods for attribute and variable data, in
addition to managerial issues accompanying new process control implementations.
Chapter 5 describes the ITCV implementation, including control point formulation, data analysis, and
requirements for long term sustainment.
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Chapter 6 discusses recommendations and future work in order to make the ITCV implementation more
robust and enduring.
2 Background and Industry
Amgen is a major biologics manufacturer headquartered in Thousand Oaks, California. A large portion of
Amgen's organization is dedicated to research and development-however, the focus of this thesis is on
the clinical manufacturing organization in Thousand Oaks and its effort to scale up clinical production of
autoinjectors, a type of combination product.
As mentioned initially, product quality is a major focus at all levels of Amgen's organization. All
employees understand that poor product quality directly affects the lives of patients and caregivers, and
thus quality rules the day. This characteristic of "quality-mindedness" is a state that many other
organizations struggle to achieve. Juran states:
"The principle force fbr securing compliance with the specifications lies not in the gages,
instructions, or other facilitiesfbr inspection. It lies in the state of mind of the plant
personnel, from the top executives down to the man at the machine... Lacking a state of
quality-mindedness among the personnel, no amount of investment in measuring devices
and ficilities can attain satisjctory control [1].
This makes Amgen's clinical organization a particularly fertile environment for implementing quality
control measures, as everyone from management to floor staff is eager to cooperate and further bolster
product quality. As Amgen's clinical organization ramps up production of combination products, new
statistical tools are required to enable quality control of new types of processes.
2.1 Combination Products
The term biologics is a portmanteau for biological products-a term defined by the United States Food
and Drug Administration (FDA) as "any virus, therapeutic serum, toxin, antitoxin, or analogous product
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applicable to the prevention, treatment or cure of diseases or injuries of man... [2]" Essentially, biologics
are molecules produced by biological processes and are generally significantly more massive and
complex than pharmaceutical products produced through chemical synthesis.
Traditionally, biologics are packaged into vials or syringes and administered to the patient by a doctor,
nurse, or other healthcare provider in a controlled setting. However, this medium is not always convenient
for a patient. A cancer patient receiving biologics often needs to drive to a hospital or clinic to receive his
dosage of a cancer biologic after chemotherapy-a daunting proposition when the patient is at his
weakest. Increasingly, the biologics industry is turning to alternative drug delivery methods to increase
patient ease and quality of life. Amgen, along with other industry players, is engaged in an effort to
integrate biologics into medical devices to enable a final product that is more patient friendly. Amgen is
coming to realize that these specialized delivery platforms can be a significant business driver:
"Our products' competitive position among other biological and pharmaceutical
products may be based on, among other things, safety, efficacy, reliability, availability,
patient convenience/delivery devices, price, reimbursement and patent position and
expirations [3]."
These hybrids of medical delivery devices and biologic products are known as combination products.
Combination products are broadly defined by the FDA to be any combination of drug, devices, and
biologics in a single product embodiment [4]. These subparts of a combination product are known as
constituent parts of a combination product, and have distinct regulatory identities in the eyes of the FDA.
Combination products present a unique challenge for biologics manufacturers such as Amgen-with
quality systems geared to produce drug products with high precision, physical manufacturing processes
and physical components lie outside current quality practices in the clinical organization.
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2.2 FDA Regulatory Requirements
The FDA is broadly divided into various centers and offices, of which the Center for Biologics Evaluation
and Research (CEBR), Center for Devices and Radiological Health (CDRH), and Center for Drug
Evaluation and Research (CDER) are the most relevant to this thesis. Title 21 of the Code of Federal
Regulations governs all arenas in which the FDA has oversight. Medical device manufacturer are
regulated by Part 820 Quality System Regulation (QSR), which is structured more generally in the style
of International Organization for Standardization (ISO) quality systems. Pharmaceutical and biologics
manufacturers are regulated by Part 210/211 Current Good Manufacturing Practice (cGMP).
Although the QSR and cGMP quality systems overlap extensively, there are specific areas of variance due
to the differences between drugs and medical devices. In January 2013, the FDA issued the final guidance
regarding combination product cGMPs which becomes effective in July 2013. This new guidance reflects
the changing landscape of combination product regulations. Currently, regulatory jurisdiction is
established based on the constituent parts of the combination product. A draft guidance published in 2004
indicates that combination products will be primarily regulated by the constituent part that enables the
products primary mode of action. For biologics manufacturers such as Amgen, this generally means that
no massive quality system overhauls are necessary as long as the primary mode of action of the
combination product is within keeping with the current quality system. However, combination product
manufacturers are required to adhere to the quality regulations that are relevant to each constituent part. In
the case of Amgen's combination products, this indicates that the biologics constituent part continues to
be regulated by the cGMP system currently in place, and that the device components should be regulated
by QSR principles [5]. The table provided in the FDA combination product guidance in Figure 1 below
indicates the areas a manufacturer following either cGMP or QSR should consider adding as supplements
to the current quality system. Amgen is currently working to ensure that these QSR combination product
principles are built into Amgen's business processes.
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Table 1: Key Current Good Manufacturing Pracitie Provon. to Conekldr During
and Anar Join"n T1sMer co wiae d siglestty omnon Produt
N th Operatng Manufaeturing control Systen Is Part 820 (QS Reguladon) If the OperatIng Manuf aturing Control system ks Part
210211 (COMP Regulation)
careftuy Consider These Two Caremfly Coneldur Thes TN*
SpecifIC COMP Requrements Speofi QS Requiement.
1211.84 Testing and approval or rejecton of §820.30 Design controls
comrponent drug product containers, and
closures
§ 211.103 Calculation of yIeld § 820.50 PurchasIng convois
§211.137 Expbton dating 1820.100 Correctve and
_prevenltve act"o
§ 211.165 Tstng and release for distribution
§211.166 Statitty testing
1211.167 Specialtestng requirements
§ 211.170 Reserve sanples
Inluding all subsections, as appropritae.
Figure 1. Regulatory guidance for combination product manufacturers
Ultimately, combination product manufacturers must adapt their current quality systems to expand to
meet the regulatory needs of combination products. This is especially important for manufacturers who
primarily produce only one constituent part-the additional constituent parts of the combination product
are not typically core competencies and require further scrutiny.
Both systems largely employ similar terminology that will be used throughout this thesis:
e Nonconformance - Any instance where a product or process does not conform to its
specifications
* Corrective and Preventative Action (CAPA) - Generally formulated in response to a
nonconformance. This is a concerted action to correct a causal factor of a nonconformance.
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2.3 Product Lifecycle
Biologics-Device combination products follow a different lifecycle pathway from either a biologic or a
device alone. As a primary biologics manufacturer, Amgen faces challenges in aligning project
management business processes to integrate device development teams and drug development teams.
According to QSR, devices typically undergo design controls during the development phase. These
design controls consist of a number of reviews, gating items, and checkpoints to ensure risk management
and quality management is inherent in the design from the onset of development. Device development
timelines are generally significantly shorter than drug development timelines, which can require that a
biologics manufacturer develop specific internal organizational processes to align workflow.
The generic launch pathway followed at Amgen is as follows in Figure 2:
Combination Product Lifecycle
Figure 2. Process description of combination product launch
Pre-clinical Drug Development - These activities include drug discovery and development and generally
begin a number of years in advance of device development. Initial pharmacokinetic and
pharmacodynamics studies are conducted, in addition to in vitro and animal studies assessing drug
viability and safety.
Clinical Trials - Clinical trials are a systematic way of gathering data to support claims for the safety and
efficacy of the proposed drug.
Phase 1 Trials - The first stage of clinical trials is aimed at assessing drug safety. A pool of volunteers
are drafted, and dosage levels are established. The volunteer pool is usually well below one hundred
volunteers.
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Device
Development
Phase II Trials - The second stage of clinical trials is intended to evaluate the biological activity or effect
on the human body. The trial patient pool is generally larger at around a few hundred volunteers.
Device Development - As a drug is progressing through initial clinical trials with positive results, the
need for a device delivery mechanism is assessed as the end patient use scenario is evaluated. Although
the exact device development timeline will vary in every scenario, generally development will begin after
the intended drug has reached a fairly mature stage of development.
Phase III Trials - The third stage of clinical trials is intended to assess efficacy and safety of the drug on
the intended clinical intervention. The pool of volunteers can number up to a few thousand. At this point,
it is assessed whether a delivery device should be integrated with the drug, and stability, bioavailability,
and human factors considerations are assessed. Based on the new regulatory landscape discussed
previously, the FDA has requested that the finished combination products undergo phase III clinical trials,
in addition to the drug alone. This is to assess any adverse reactions associated with the combination
product as a whole, such as differences in bioavailability. The consequence of this requirement is that the
delivery device must be largely production equivalent prior to the clinical trial.
Scale Up Activities - These activities generally include manufacturing scale up, and are ideally timed to
coincide with FDA approval of the product.
Commercial Launch - After FDA approval, the combination product can be commercially sold. However,
as mandated by both QSR and cGMP, post-launch surveillance must be in place to monitor for adverse
events and quality issues. At this point, the product is transferred to commercial manufacturing sites.
2.4 Clinical Production Environment
Amgen is broadly structured into various commercial manufacturing units, and a clinical manufacturing
unit based in Thousand Oaks, CA, which supplies clinical trials with product. By necessity, clinical
manufacturing must be a flexible organization. Volumes for clinical products are comparatively lower
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than commercial products, and are by nature at a lower level of scale-up than commercial products.
Namely, products are often produced in small batches, dedicated production lines rarely exist, and
changes in formulation must be implemented quickly. Clinical production is a non-revenue generating
activity-however, clinical products must adhere to the same high levels of quality as commercial
products. These factors often make clinical production a challenging environment for many companies.
The clinical production unit at Amgen operates as a microcosm of the commercial production units with
many of the same functional divisions, but at a significantly smaller scale. Upstream teams manufacture
drug product and placebo, formulate the dosages, and fill vials or syringes (known as primary containers).
The clinical packaging team then labels and packages the primary containers in a blinded fashion-such
that placebo and true drug product are indistinguishable at the clinical site. Product is then distributed to
clinical sites around the world. This thesis will largely focus on the clinical packaging team and their
efforts to ramp up autoinjector production.
2.5 Autoinjectors
Autoinjectors are a common type of disposable combination product used to semi-automatically deliver a
specific dosage of drug.
Figure 3. Image of an autoinjector [61
Generally these devices consist of a spring-loaded ejector system and a drug filled syringe. When a
trigger is depressed, the spring uncoils and delivers the drug contents. As mentioned before, these
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autoinjectors enable patients to administer doses to themselves, instead of taking a trip to their healthcare
provider. The basic method of use is shown in Figure 4:
step one: remove the needle cover. step two: press and hold the DAl" step three: press and release the ac-
against the injection site to automat- tivation button to begin delivery. An
ically release the safety interlock. audible "click"will sound at the start
and end of the injection.
Figure 4. Instructions for how to use an autoinjector 161
Autoinjectors have been most widely used to deliver epinephrine, in the event of anaphylaxis caused by
an allergen-these autoinjectors are termed "EpiPens." Previously, stabilizing biologics for potential
integration with an autoinjector has presented a challenge. Amgen has overcome this challenge in recent
years.
3 Problem Description
This thesis describes the implementation of a process control system on the Amgen clinical autoinjector
assembly line. As mentioned before, autoinjector assembly is a new process in the clinical setting, and
new quality control processes are required to support this effort.
3.1 The Identify, Track, and Control Variation (ITCV) Program at Amgen
Identify, Track, and Control Variation (ITCV) is an Amgen tool for a method of process control. This
program has historically been implemented in various commercial settings in order to address specific
quality concerns. As mentioned before commercial statistical process control techniques are different than
those used in the clinical setting. For example, ITCV was successfully implemented at Amgen
Manufacturing Limited (Puerto Rico) to proactively address trends identified in combination product
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complaints. Ideally, ITCV has the potential to ultimately become a quality tool that is implemented as part
of a standard quality procedure during process ramp up in both the clinical and commercial production
environment. ITCV captures the intent of statistical quality control quite well, illustration the program as
a cyclic, evolutionary process. However, ITCV is not broadly implemented within Amgen, and
particularly less well known within the clinical manufacturing organization at Amgen Thousand Oaks.
Continuous Improvement
Inputs include:
Design FMEAs Using process documentation and Self-directed teams using SPC process and tools to detect
Process FMEAs control plan template trends and out-of-control events.
BOMs Monitoring the SPC process itself for continuous
Equipment characteristics improvement.
Process characteristics
Maintenance studies
Figure 5. ITCV process diagram
Commercial implementations of ITCV do not necessarily meet the particular requirements for clinical
production. Specifically, clinical autoinjector volumes do not merit the use of expensive automation,
vision system equipment, and integrated IT systems. As a result, the ITCV program is not currently
widely implemented in the clinical packaging space. However, the inherent underlying framework of
ITCV, as depicted in Figure 5, is a sound and logical approach for attacking the new challenges that
autoinjector assembly brings to the clinical packaging unit. Furthermore, developing ITCV control plans
in the clinical setting allows for early identification of important control points when processes are scaled
up in the commercial setting. This framework forms the basis for the process control implementation
detailed in this thesis.
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3.2 Specific Problem Description
Autoinjectors have been built previously on a small scale within the clinical packaging unit, but the new
regulations requiring devices to be included in the clinical trial process necessitates production scale-up to
significantly higher volumes. Traditionally, the clinical packaging unit has dealt primarily with packaging
vials and syringes and labeling these units in a blinded fashion. The introduction of the autoinjector
assembly process to the clinical packaging unit presents numerous challenges- increased space
requirements, new equipment requirements, increased headcount requirements, and most importantly, a
cohesive system for assessing and predicting line performance. The focus of this research project was to
implement a control system that could trend historical reject and nonconformance rates, and provide a
basis for implementing CAPAs and continuous improvement efforts. This effort was also meant to bolster
ITCV visibility as a corporate quality control tool.
3.3 The Case for ITCV implementation
The ramp-up in autoinjector production volumes is a new effort for the clinical production team. The
process risk is generally perceived as nontrivial and multiple risk mitigation efforts are being
implemented. In the face of this conservative approach, management reception for ITCV implementation
was quite positive. Implementation of the ITCV program only increases the data available to make
strategic decisions regarding the autoinjector assembly line, and react to negative trends before
nonconformances occur.
Ultimately, the body of data and associated learning from the increase production volumes will prove to
be a valuable package of information to transfer to the commercial organization upon product launch. The
ITCV program is also the first such implementation in the clinical space-lending a distinction to the
clinical packaging unit as a leading implementer of continuous improvement processes.
Although the path for ITCV implementation is generally clear, it is important to identify an organizational
structure to ensure the program is developed and maintained in an integrated fashion with both the
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manufacturing and quality unit processes. Assembly operators must not be distracted with data collection
during the assembly process, especially because they are occupied with executing the process. It is crucial
to the success of ITCV for a supporting organizational structure to be developed and formalized.
4 Literature Review
Statistical Process Control can be broadly defined as a toolkit of statistical techniques aimed at decreasing
variation and increasing quality [7]. Pioneered by Walter Shewhart at Western Electric, a subsidiary of
Bell Telephone, process control techniques are as relevant today as they were almost a century ago. Until
the early 1930s, most manufacturers were dependent on 100 percent inspection and judgment. In 1924,
Western Electric set up an Inspection Engineering Department with the purpose of developing inspection
procedures and techniques for controlling fabrication processes. Shewhart was among the personnel
assigned to this group and developed the concepts that underlie modem statistical quality control. His
concept of the control chart enabled manufacturers to make inferences about process behavior [8].
Ultimately the true power of these control techniques allow manufacturers to not only assess process
health, but to make prescient predictions of future process health. The.following literature review
addresses modem process control techniques used in implementing the ITCV program in the clinical
packaging unit.
4.1 Process Control Techniques
In the pursuit of quality control, two options are available to managers: 100% inspection or sampling.
100% inspection is only possible in cases when critical quality attributes can be measured without
destroying the product. Furthermore, 100% inspection is often prone to weaknesses such as operator error
or test equipment variation [9]. Thus, in many cases it is necessary to engage in a sampling plan. A
sampling plan requires random selection a specified subset of product, and assessment of the critical
quality attributes of that subset. Thus, the results of the quality tests performed on the subset of product
are representative of the entire product batch. Management can then make a decision to accept or reject
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the entire product batch based on these results. This thesis will not discuss the methodology for creating
and utilizing sampling plans-let it suffice as an assumption for further discussion that a sampling plan is
in place. A full discussion of sampling techniques can be found in Ott Chapter 6.
Process control techniques range from simplistic visual plotting techniques to complicated control
algorithms. Methods that are most relevant to the processes at hand in this thesis will be discussed.
Specifically, since the level of process complexity is quite low and few formal process controls are
currently in place, the simplest types of control methods will be reviewed.
Process quality control is considered to have been formally vocalized by Walter Shewhart in the early 2 0th
century. His conviction that "assignable causes of variation may be found and eliminated [10]" led him to
formulate the key technique of the control chart-a method for visualizing process performance.
This is a distinct shift from the informal level of process controls utilized in earlier decades, where
managers would either improve processes based on experience and intuition or make no attempt towards
process improvement at all. The philosophy underlying the formal control chart is to "identify and correct
for assignable causes as they occur, and thereby keep variation in the process within its natural limits
[11]."
4.2 Process Control Methods for Variable Data
Control charts are one of the most common methods for tracking variation and understanding processes.
Although many different forms of control charts exist, control charts are simply a graphical display of a
particular quality characteristic with a calculated Upper Control Limit (UCL) and Lower Control Limit
(LCL). The graphs provide a useful tool for understanding types of variation and process shifts over time.
Additionally, control charts can serve as a visual "scorecard" to operators and managers, and can be
useful motivational tools for process improvement.
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Variables with associated quantitative data (such as length, hardness, temperature etc.) can be displayed
with a control chart, assuming the distribution of the data at hand is normal. Oftentimes, data is collected
from product that is sampled from the broader population. Thus, for each batch of product produced, data
will be collected from a certain subgroup. Common types of control charts are as follows:
4.2.1 Run Chart
A run chart is a very basic control chart-simply a graphical depiction of each single data point in the
analysis range (X). A run chart often forms a good basis for beginning to understand a process, although
it does not ultimately carry the predictive power of a control chart.
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Figure 6. Run Chart of sample data
Figure 6 above depicts a data set of 200 samples, with subgroup size 20. Even without further analysis, it
is clear to see that a greater degree ofprocess variation has been introduced after the 100th sample.
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4.2.2 The X, R Control Chart
X refers to the mean of a subgroup. The means of a subgroup are calculated and plotted on an X graph. R
refers to the range of a subgroup-essentially a measure of dispersion of the data. The range is simply
calculated by subtracting the lowest value of a data set from the highest.
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Figure 7. r chart of sample data
The Range of the 10 subgroups displayed in the run chart prior is shown in Figure 7 above. It is clearly
visible that subgroup dispersion in subgroups 6-10 has increased relative to dispersion in subgroups 1-5.
In general, R is calculated with the following formula:
Ri = Xhigh - Xiow
The centerline, UCL, and LCL are calculated as follows below (control chart constants are drawn from
Appendix A):
centerline = R UCLN = D4 NR
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Figure 8. X-bar chart of sample data
The subgroup means of the 10 subgroups displayed in the run chart prior are shown in Figure 8 above. It
can be visually deduced that the means have changed based on the out of control point for subgroup 6. In
general, each point is calculated with the following formula where X refers to an individual data point in
subgroup i and n is the number or samples in subgroup i:
-E X
X, =
n
The centerline, UCL, and LCL are calculated as follows, where n refers to the subgroup size, and sigma
is the standard error (control chart constants are drawn from Appendix A):
centerline = X UCLv = X + A2 R LCLg = X - A2 R
4.2.3 The X, s Control Chart
X, s control charts are quite similar to the X-Bar, R chart discussed above. Instead of plotting R, the
standard deviation s is calculated instead. This is valuable when subgroup sizes are relatively large (n> 10)
or when the sample size is variable. Furthermore, the s statistic becomes simple to calculate when
computers are available to perform the computation.
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Figure 9. s chart of sample data
The same data set in the previous example is displayed as a standard deviation chart in Figure 9. Note
that the UCL and LCL are significantly tighter, and that the trend is more pronounced. The standard
deviation s is calculated as follows:
=1iS
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The centerline, UCL, and LCL are calculated as follows (control chart constants are drawn from
Appendix A):
centerline = s UCLg =B4s LCLg = B3§
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Figure 10. X-bar chart of sample data
Again, the same data set from the previous example is plotted. Note the slight differences in UCL and
LCL. Also note that subgroup 6 is no longer outside the control limits. With this type of analysis, it
appears that the process is still within controls. Although this data is purely fictional, this serves to
highlight the importance of choosing the appropriate type of control chart and control chart parameters.
X is calculated in the same fashion as explained in the previous section. However, the centerline, UCL,
and LCL are as follows (control chart constants are drawn from Appendix A):
centerline = X UCLg = X + A3 - LCLg = X - A3s
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4.3 Process Control Methods for Attribute Data
It is sometimes convenient to collect attribute data in place of variable data. Attribute data usually takes
the form of reject rates and nonconformance proportions. Essentially, this is a binary notation of whether
a particular issue was found or not. Since there is no numerical measurement associated with attribute
data, a typical control chart cannot be used to provide meaningful data. However, various control charts
exist that allow for plotting attribute data.
4.3.1 Thep Chart
This chart exerts control based on the proportion of defective units per batch. Control limits can then be
calculated for proportion defective. The p chart is also a good visual depiction of overall quality, as it can
give an indication of overall defects for a process. One drawback to the p chart is that no information on
the types of defects is included. A pareto chart, to be discussed below, is necessary to provide further
insight into the sources of variation an defects.
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Figure 11. p chart of sample data
The]p chart depicted in Figure 11 consists of sample data, and depicts a process that appears to be in
control. The p statistic is calculated as follows, where np is the number of defects within a sample, and n
is the sample size:
np
n
The centerline, UCL, and LCL are calculated asjbllows:
centerline = p
UCL#= f+ 3 n LCLg= P-3 n
4.3.2 The Pareto Chart
Named after Vilfredo Pareto (1848-1923), the pareto analysis was originally used to study the distribution
of wealth in Italy. Pareto found that 80 percent of the wealth belonged to 20 percent of the population.
This, in addition to various studies performed over the years in other fields, gave rise to the "80/20" rule,
where 20 percent of inputs are correlated with 80 percent of the outputs [12]. Juran applied this principle
to quality to distinguish between the "vital few" and "trivial many [12]." A pareto analysis is used today
in quality analyses to understand the frequency of various issues contributing to nonconformances.
A pareto chart is constructed by assembling a cumulative distribution of the causes of variation, and is
often paired with a bar graph of the causes. An example is as follows [13]:
Given the following data regarding operators and defect counts:
Operator Count
1 A 4
2 B 10
3 C 0
4 D 22
5 E 2
6 F 8
7 G 4
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We can reorder the operators from high to low, and calculate what percent of total defects each individual
is responsible for. A cumulative percentage is also recorded.
Cumulative
Operator Count % %
4 D 22 44% 44%
2 B 10 20% 64%
6 F 8 16% 80%
1 A 4 8% 88%
7 G 4 8% 96%
5 E 2 4% 100%
3 C 0 0% 100%
Total 50 100%
The results are graphed below:
Defect Count by Operator
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Figure 12. Pareto chart analysis of sample data
Although the example is simplistic, the pareto chart in Figure 12 clearly illustrates that operator D causes
significantly more issues than the other operators. This method is a simple way of highlighting causal
factors.
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4.4 Implementation of Quality Control Procedures in Organizations
Various challenges can arise when attempting to implement new quality control procedures in an
organization.
4.4.1 Resistance to Change
The introduction of any new procedure or policy invariably encounters resistance in an organization,
largely due to social or cultural reasons. Disruption of the cultural pattern within an organization is often
difficult to avoid when implementing new process control techniques. Juran offers an enlightening
checklist of advice to the process control champion:
1. "Secure the active participation of those who will be affected during both the planning
and the execution of the change.
2. Strip off all the technical cultural baggage not strictly needed fbr introducing the change.
(Many quality control engineers have been in violation of this.)
3. Reduce the impact of the changes by weaving them into an existing broader pattern of
behavior, or by letting them ride in on the back of some acceptable change.
4. Put yourself in the other fellow's place.
5. Make use of the wide variety of methods available for dealing with resistance to change.
6. Treat people with dignity [14]."
This checklist, although formulated in the 1960s, is still largely relevant for organizations today.
4.4.2 Employee Evaluation
Control charts are useful because they provide a metric for evaluating a process. However, control charts
not only reflect performance of a process, but can represent the underlying performance of the floor
operator. Different scenarios can ensue:
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e It may be useful for an organization to track individual operator performance. This can be used as
an input to setting compensation or evaluating for promotion. This data can provide the hard facts
to ensure that employee compensation is fair and transparent [15].
e Using control charts as a report card can also have a deleterious effect on employee morale. If a
statistical system is in place for tracking individual performance, but is not used for personnel
decisions or is used incorrectly, "everybody will suppose that there are good reasons for the
selection and will be trying to explain and reduce differences between people [1 5]."
e Even if a control chart for tracking individual performance is in place and is appropriately used,
such a system can destroy employee fraternity. If employees are competing against each other,
the environment of teamwork is lost, and can have negative results on overall morale [15].
Thus, it is important to utilize such systems for tracking operator performance wisely, and ensure that
morale remains high.
4.4.3 Qualified Personnel
It is important to ensure that qualified personnel are associated with implementing process control
change. A combination of a basic understanding of statistical terminology, familiarity with local business
processes, and quality methods is required to effectively implement new process control strategies.
Ultimately, it is necessary that the organization source effective personnel to ensure that the quality effort
succeeds.
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5 Clinical Process Control Implementation
5.1 Process Description
In the final implementation of the auto injector assembly line, the process flow is as follows in Figure 13:
Manual Autoinjector
L ~Assembly J
Press Step 1
Press Step 2
Random Samples Drawn
-> Autoinector Inspection
(SATM)J
Activation Force
Injection Time
Injection Volume
Figure 13. Process flow diagram of autoinjector assembly and inspection process
Autoinjectors consist of three main components as shown in Figure 14:
e Pre-filled syringe (PFS) containing a predetermined dosage of drug
e Rear shell containing spring-loaded ejector system and button trigger
- Front shell containing removable needle guard and clear window to confirm injection of the full
dosage
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Figure 14. Autoinjector component breakdown [61
Assembly consists of 2 manual press operations as show in Figure 15 and Figure 16:
e Alignment of the PFS within the front shell (Press 1)
" Press fit of the rear shell with the front shell (Press 2)
These manual presses are mechanical presses that align and press fit components together. A crank handle
serves to activate the main head of the press downwards.
Figure 15. Assembly press 1 Figure 16. Assembly press 2
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These units are then sampled and destructively tested on the Semi-Automatic Testing Machine (SATM)
as depicted in Figure 17 and Figure 18. The SATM activates the autoinjector trigger and records
activation force, injection time, and injection volume. These three variables are not measured
separately-instead they are measured from a single test sequence when the product is activated. Each
batch is analyzed for excursions, and if an excursion is found, a nonconformance is logged and the batch
is quarantined for further review.
Figure 18. Close-up view of SATM test head
5.2 Process Risk Analysis
The control plan has been initially formulated based on a Process Failure Mode and Effects Analysis
(FMEA) conducted by a cross functional team. Specific representative samples of the PFMEA are show
below in Figure 19. Scoring is omitted.
Manual Press Front
Assembly
Misalignment of
syringe on the
press
Broken syringe (Gross
breakage)- CCI
Infection
Human Error
Manual Press Front Misalignment of Broken syringe (visible
Assembly syringe on the cracks)- CCI Infection Human Errorpress
Autoinjector testing in the Failure to test the Production delaye Human errorSATM (Syringe Automated samples reconciliation issues. Huaero
Testing Machine)
SATM Test for injection time .Equipment failure - incorrect
and volume (Module C) False Pass Painful injection injection time parameters - injectiontime too long - software defect
Figure 19. Table of selected PFMEA examples
These Failure Modes are a sample of the level of granularity of the PFMEA. This in-depth review
highlights that the major concerns of the cross-functional team include human error and SATM
malfunction. These are major inputs to the control plan.
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5.3 Control Point Formulation
The PFMEA discussed above forms the cornerstone for control point formulation. The majority of failure
modes identified in the PFMEA have the associated cause of "operator error." As a largely manual
process, this is natural. As a result, the control plan focuses largely on areas of operator error.
Autoinjectors also have batch release characteristics that are required to be measured before a lot can be
released. These requirements included the SATM test parameters of injection time and deliverable
volume. As mentioned earlier, the SATM collects injection time, deliverable volume, and activation force
data during the same test sequence-thus activation force is also collected and analyzed despite being a
less important characteristic than injection time and deliverable volume.
The final control points are formulated based on initial assembly run data. During assembly of the first
batch, it became apparent that there were rejects that could not be categorized into any of the pre-
formulated categories. Thus, new categories were added to accommodate for new types of rejects.
The complete control chart is presented in Appendix B and includes control limits and control activities.
The various control points are discussed below in Figure 20. Note that a particular rejected unit can be
associated with multiple control points. For example, an autoinjector that was dropped and resulted in
breakage of the syringe would be categorized with "Improper Handling" and "Glass Breakage." Type
denotes the type of characteristic, attribute or variable, as discussed before.
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Control Point Location Type Description
Gross Autoinjector Defects Assembly Attribute Any visible defect including, but not limited to:Area chips, scratches, cracks, and discolorations.
Glass Breakage Assembly Attribute Units with observed glass breakage.Area
Units where the appropriate proprioceptive feel was
Abnormal Sensation During Press Assembly Attribute not observed during press stroke. This was an
Stroke Area observed issue in initial runs, and was retroactively
added to the control plan.
Assembly Any units dropped to the floor, and any units withImproper Handling Area Attribute inserted syringe that are dropped to the floor or
table.
Misalignment During Assembly Assembly Attribute Misalignment is observed during first press step.
(Rear) Area
Misalignment During Assembly Assembly Attribute Misalignment is observed during second press step.
(Front) Area
Syringe barrel does not fit into nest on first press,
and thus press step cannot be completed. This issue
Syringe Barrel Dimension too Assembly Attribute was observed repeatedly in an isolated batch and
Large for Press Area originally logged as "other." It was then
retroactively added to the control plan and
formalized as a category.
This is intended to be a "catch-all" category to track
issues that are not explicitly assigned a category.
Other Assembly Attribute When a reject is tagged as other, it is required that aArea description of the issue be included. When an issue
makes multiple appearances, it is formalized as a
category.
Activation Force SATM Variable Force (kg) required to depress autoinjector
activation button.
Injection Time SATM Variable Time (sec) required for autoinjector injection to
complete upon activation.
Deliverable Volume SATM Variable Volume (mL) of drug product delivered by
autoinjector.
Figure 20. Table of control points
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5.4 Data Collection
Attribute data is collected by floor operators using a specifically developed electronic data collection
spreadsheet. When a defect is noticed at a press station, the press operator will raise his hand and give the
unit to the floor manager. The floor manager then enters the relevant information into the entry form
depicted in Figure 21. The floor users only have access to the entry form, and the submitted data is locked
by password to prevent any tampering. Furthermore, constraints are placed on all the data entry fields to
ensure the correct type of data is entered-for example, a numerical value must be entered into the batch
number field. Additionally, a notes section is available for additional notes.
Figure 21. Defect logging entry form
SATM data is not collected by the streamlined process described above. Data is located locally on the
machine hard drive, forcing the data collector to physically travel to the machine and export the data. This
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process requires a significant amount of time for the analyst, and is a significant constraint of the current
process. As volumes rise and more data is generated, it is unreasonable to expect that a significant
percentage of personnel time is devoted to data collection. It is hoped that additional IT resources can
automate this process in the future and eliminate this constraint.
5.5 Analysis and Trending (Attribute Data)
Due to the nascent nature of the autoinjector assembly process, attribute data was collected on a 100%
inspection basis. For each of the attribute quality variables, each press operator was instructed to reject
any product that appeared to be nonconforming. Thus, every unit was inspected during assembly.
5.5.1 Overall Process Health
Two similar charts were used to assess the overall health of the assembly process. Instead of a pure ratio
as described in section 4.3.1 discussing p charts, fraction of defective units was displayed in defects per
million (DPM) because it is a familiar quantity to Amgen clinical packaging team members.
Furthermore, the control limits of a traditional p chart would merely be distracting because of the varying
autoinjector build sizes (see Appendix C). The first chart displays DPM versus batch number (in
chronological order). This indicates general performance from batch to batch.
DPM per Batch
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Batch
Figure 22. DPM per batch by batch number
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Figure 22 clearly illustrates the "learning curve" phenomenon. Initial batches resulted in higher defect
rates, and gradually improved to settle into a lower defect level, demonstrating that the organization is
gaining economies from repetition. It is important to note that two builds consisting of about 10,000 units
in sum were conducted before the ITCV data collection system was implemented, and thus the entire
learning curve is not captured.
The next graph to assess overall process health considers the factors of time and batch size. DPM is
plotted against the date, and bubble size indicates the relative size of the build.
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Figure 23. DPM per batch by time. Bubble size indicates batch size.
Figure 23 allows manufacturing personnel to understand whether operator fatigue is contributing to defect
rates. It is theorized that operators could potentially experience fatigue if a batch is particularly large or if
builds are performed on consecutive days. It is important to note that builds are usually performed over a
single day, regardless of batch size. If a batch is small, fewer operators are engaged. If a batch is large,
more operators are scheduled and overtime is utilized. However, no significant evidence is visible from
the results of this graph to identify the presence of operator fatigue. It is important to monitor this graph
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over time, and perhaps perform a more in-depth statistical analysis when a larger data set has
accumulated.
5.5.2 Causal Factors Analysis
For each reject logged, information on the operator press station was also collected. From this data, it is
possible to perform a pareto analysis analyzing the distribution of press stations where rejects were
identified. This allows manufacturing personnel to assess whether a particular press is having mechanical
issues. Unfortunately, operators are not currently constrained to sit at the same presses, and the same
subset of operators is not always present for a build. Thus, it is not possible to use this information to
trace back to a particular operator. A pareto analysis of press stations logged in the months of November
and December is shown below. Over 100,000 units were assembled within this time period.
Total Issues Reported by Press Station
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Figure 24. Pareto analysis across press stations
Press stations 6 and 7 are not used when smaller builds are performed, and thus have a noticeably lower
issue count. There does not appear to be a striking visible difference between the remaining press stations
in Figure 24, however it is important to perform a statistical analysis to confirm this when more data has
been collected. Ideally, the granularity of the data collection system could be increased to include a tie to
the operator. Some operators may be more zealous in observing and flagging rejects, and some operators
may be less adept than others. Any implementation of this kind would need to be done cautiously, so as
not to seem like a method for criticizing individual performance.
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A pareto analysis of rejects logged in the months of November and December is shown below in Figure
25. Over 100,000 units were assembled within this time period.
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Figure 25. Pareto analysis by issue type
Abnormal sensation, improper handling, and misalignments account for approximately 80% of the issues
observed. This leads to interesting recommendations regarding corrective actions.
Abnormal sensation during press stroke-Currently, abnormal sensation units are rejected in
order to take the most conservative approach to reject segregation. It is currently unknown
whether a deviation from the normal proprioceptive feel of a press stroke indicates the presence
of a deviation. Since these units form the greatest fraction of rejected units, it is natural to analyze
the failed units to determine whether this ambiguous causal factor truly forms a basis for
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rejection. It is recommended that units tagged with the abnormal sensation issue be segregated
and tested to determine whether any defect can be observed in appearance or in function.
The other rejection categories do not present a pressing need for analysis or corrective actions at the
moment. Although it is ideal for process improvement to advance upon all fronts, rejection categories
with constant low levels should be considered as part of the baseline human error for the process. For a
relatively small manufacturing environment, diminishing returns are obtained by trying to completely
eliminate small sources of error.
Improper Handling-Improper handling can only be reduced with proper operator training and
care. However, it is unlikely that improper handling can ever be eliminated due to the manual
nature of the process. As long as this causal factor can be controlled and a constant low level,
there is no reason to address the issue.
Misalignment-Misalignments appear to occur with roughly similar frequencies in press step 1
and press step 2. This may be due to a combination of operator error, or equipment error. It is
recommended that this category be monitored for issues associated with any one press station or
operator to ensure that misalignments are not associated with any particular causal factors.
Other-The rejection tag of "other" consists of various rejection scenarios. Until a rejection
scenario becomes significant enough to warrant creation of another formal category, these
scenarios are tagged as "other" in the data logging system and the operator enters an explanatory
note. Scenarios within this data set include:
* Double insertion - operator forgets that he has already aligned syringe within rear assembly
at press step 1, and inserts a second syringe. This causes glass breakage and damage.
e Needle cap falls off - when the needle cap is removed from the syringe, the drug product is
no longer usable.
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" Visible sediment in syringe - when visible sediment is observed within the syringe, the
product is not used for cosmetic reasons.
e Autoinjector jumped in nest - operator notices that the autoinjector shifted in the nest during
the press stroke. Although this is a soft causal category similar to abnormal sensation, so few
units have been tagged with this note that it does not merit immediate attention.
5.6 Analysis and Trending (Variable Data)
The following data is obtained from sampled product subgroups destructively tested on the Semi-
Automatic Testing Machine (SATM) discussed above. Each sampled subgroup consists of 49 units,
although in the initial test batches, some data was lost due to machine error and differing file naming
conventions. Three subgroups are sampled from the beginning, middle, and end of each production batch.
An X, s control chart was chosen as the vehicle of analysis for the quantitative quality variables, because
subgroup sizes are large (n>10) and the initial subgroups vary in size due to the aforementioned reasons.
Results for the three major tests will be discussed.
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5.6.1 Activation Force (ATF)
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Figure 26. Run chart of ATF
From the run chart in Figure 26, it is easily observable that a process shift has occurred somewhere
between sample #522 and sample #1218. It is interesting to note that the shift is gradual-indicating that
the reason for the variation did not occur instantaneously. In the following control chart analysis, the data
has been split into phases A, B, and C to represent the original process state, transitional process state, and
new process state, respectively. The specification limits are shown in blue-note that the original process
state is biased towards the upper specification limit.
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Figure 27. s chart of ATF
A normality check was performed, and individual subgroups appear normal (see Appendix D). The s-
chart for the ATF parameter depicted in Figure 27 appears to be reasonably in control within phases A,B,
and C. The large spike in phase A is due to an operator error failure, and has been investigated. These
results are encouraging, because they indicate the variability within each subgroup is relatively in control.
However, the increase in mean standard deviation from Phase A to Phase C indicates that overall
subgroup dispersion is increasing. Ideally, the mean standard deviation (indicated by the green line on the
graph) would move in the downward direction on the chart. Since the intra-subgroup variability appears
to be in control, it makes sense to move on to analyzing inter-subgroup variability via the x-bar chart.
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Figure 28. X-bar chart of ATF
The suggested trend that was visible in the original run chart is now quite clear in the x-bar chart in Figure
28. Limits calculated on a 3 sigma basis for each phase are shown in red. Between Phase A and Phase C,
a definite process shift has occurred. Since this trend appears to be gradual, a few theories as to the source
of variation arise:
The supplier of the autoinjector components have enacted a process change, resulting Phase B
where old and new components were in use and ultimately Phase C where the process has
stabilized to the new level.
o The next step in this investigation is to obtain outgoing testing results from the
component supplier. The supplier uses the same SATM to test sampled outgoing
autoinjectors before distribution to Amgen-thus it will be beneficial to compare testing
results over the transitional period to understand whether they have seen similar results.
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e The SATM could potentially be undergoing some form of wear, causing results to gradually trend
upwards.
o Upon investigation, this w'as found not to be the case. The machine was investigated and
still found to be equivalent to the original equipment validation performed and within
calibration.
For a data set with a distinct phase shift as shown, it does not make sense to calculate control limits for
the entire data set. Instead, control limits should be calculated for the distinct phases. When the control
limits are tripped, it is clear that the process is out of control. A corrective action should then be
implemented. At that point, new limits should be calculated, set, and monitored for tripping. This is an
ongoing cycle as long as the process is shifting. This is the prescient power of the control chart-phase II
predicted phase Ill.
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5.6.2 Injection Time (IJT)
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Figure 29. Run chart of IJT (Active and Placebo)
Plotting a basic run chart before any in-depth analysis has been performed has proved useful again. Even
without any calculation, it is visibly apparent in Figure 29 that there are two distinct bands of data-the
first at approximately 7 seconds and the other at 4 seconds. It is also visible from the groupings of three
(beginning, middle, and end) that subgroups from the same batch behave similarly. Upon closer
investigation, it was concluded that autoinjectors containing placebo had a faster injection time than
autoinjectors containing active drug product. Thus, for the control chart analysis to follow, data is broken
out into respective placebo and active graphs. Note that the specification limit for this variable is one
sided, and is indicated by the blue line.
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Figure 30. s chart of Active IJT
A normality check was performed, and individual subgroups appear roughly normal (see Appendix D).
Unlike activation force, the intra-intra subgroup variability does not appear to be in control in Figure 30.
The dispersion of each subgroup appears to be varied and wide.
Before attempting to control variability between subgroups, it is logical to first attempt to control
variability within a subgroup.
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Figure 31. X-bar chart of active IJT
The X-bar chart depicted in Figure 31 implies that variability between subgroups is not in control. As
explained above, variability within subgroups should first be within control before attempting to control
variability between subgroups. The results for placebo product exhibit very similar characteristics and are
included in Appendix E.
Injection time is largely a function of the pre-filled syringe (PFS) that is loaded into the auto-injector and
the tolerance on the spring-loaded ejector mechanism in the Rear Assembly of the autoinjector.
Recommended investigative actions include:
e Perform a study or obtain vendor data for ejector mechanism to ensure variation is not present
e Consult with upstream drug product team to understand viscosities of product present in the PFS.
From the run-chart, it appears that all of these values are well below the specification limit. It is tempting
to assume that the control chart is irrelevant. However it is important to control the variability within the
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subgroups and from subgroup to subgroup to ensure that the process is in control and behaving as
expected. Significant variations in production can potentially lead to excursions from the specification
limits down the line, if left uncontrolled.
5.6.3 Deliverable Volume (DLV)
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Figure 32. Run chart of DLV
Again, the run chart in Figure 32 provides interesting visual insight. The specification limit, shown in
blue, is one sided. There are no significant excursions dipping towards the specification limit, but many
excursions away from the specification limit. Although it is positive that there seems to be no danger of
failing the specification, these upwards excursions can potentially indicate waste and lowered yields.
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Figure 33. s-chart of DLV
A normality check was performed, and individual subgroups appear roughly normal (see Appendix D).
The s chart in Figure 33 indicates that the variability within subgroups is not in control. This confirms the
initial suspicion observed in the run chart due to the presence of numerous upwards outliers within
individual subgroups.
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Figure 34. X-bar chart of DLV
The X-bar chart in Figure 34 indicates that variability between subgroups is not in control.
Deliverable volume is solely a function of the PFS. The first step towards attempting to understand the
intra-subgroup variability is to analyze upstream data. Syringes are filled in the aptly named Filling
Process, and checkweigh data is gathered before transport to the packaging unit to ensure that all syringes
are above the specification limit. This variation is indicative of variation upstream of the autoinjector
assembly process, and the Filling process must be stabilized to ensure stable results after final assembly.
Again, all points are fairly well above the specification limit. It appears that there is no cause for concern.
However, overfilling PFS over time will lead to lowered yields. The clinical drug production team often
struggles for yield increases, so overfilling the PFS is an unnecessary waste of product. It is important to
bring the process into control in order to ensure the maximum quantities of product.
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5.7 Monitoring
Because this data collection and analysis effort occurred at the beginning of the process lifecycle, new
data was reviewed often. A cross-functional team consisting of the floor manager, quality representatives,
manufacturing representatives, and statistical expert convened weekly to analyze the data. A convenient
dashboard was created to analyze the assembly reject data and is shown in Figure 35 below:
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constraint of the current process. See section 6.1 for specific recommendations.
This meeting serves as an important platform for discussing the state of the process, and the need for
potential corrective actions. Although data collection forms the foundation of ITCV, it is equally
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important to ensure that the data is presented appropriately and that relevant staff have access to the
analysis. At the end of December, it was recommended that in-depth review occur on a monthly basis
since the assembly process had largely stabilized.
5.8 Sustainment
5.8.1 Ownership and Accountability
It is important to ensure that a leader for the ITCV program be identified. This owner is then accountable
for ensuring data is collected and analyzed, and appropriate review periods are scheduled. A current issue
is the existence of multiple quality groups. The clinical packaging group, the drug product manufacturing
group, and the combination product devices team all have independent quality groups with some stake in
the process. Although these quality groups are united under a senior quality leader, there is ongoing
discussion as to where responsibility boundaries should be drawn. Thus designating a clear understanding
of ITCV ownership is important to a reliable quality control process.
Additionally it is important to note that integrating quality into manufacturing processes ultimately
streamlines quality assurance down the line. ITCV is one example of a method for integrating quality into
manufacturing processes. Floor ownership of quality control efforts is also imperative. Cooperation and
enthusiasm for the ITCV program was found to significantly increase when data and results were
reviewed with the operators. ITCV results are a direct measure or report card for floor operator and floor
manager performance. Although upper level managers are interested in ITCV data as a measure of
process health, floor operators and floor managers view this data to be a direct assessment of their efforts.
Thus, operators and managers were more willing to invest time into ensuring that quality data was
collected. It was found that sharing this data with floor staff helped this author make subsequent progress
on implementation efforts and make friends.
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5.8.2 Training and Documentation
Proper training and documentation is key to the success of ITCV implementation. A pareto analysis of all
collected batches is shown in Figure 36. Note that "Other Issue" appears to be the most prevalent
category. This can be explained by the first batch of data collected. Instead of taking the time to log each
reject with a specific category, operators found it faster to select "Other Issue" without entering any
explanatory notes. The electronic data entry form was subsequently modified to mandate an explanatory
note if "Other Issue" was selected. As a result, this initial batch has been excluded from all data analysis
presented above.
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Figure 36. Pareto analysis including data resulting from poor initial training and messaging
This scenario is an example of inadequate change management on the part of this author. It was the
responsibility of the author to ensure that this initiative rolled out smoothly - however, all floor operators
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were not formally trained regarding the ITCV program before data collection efforts began. Some
operators may not have initially understood the purpose of the program, and viewed the extra data logging
steps as additional work on top of existing work. Selecting "Other Issue" may have shortened the amount
of time an operator would spend logging information. However, with appropriate training, the quality of
the data was greatly improved as the operators were informed of the purpose of ITVC. It is essential that
operators understand the importance of data collection and analysis. Additionally, a program constraint
was added to require entry of a note if "Other Issue" was selected. ITCV is driven by operator
compliance, and ultimately, floor operators have the best ability to suggest modifications and
improvements to the data collection process.
5.8.3 Continuous Monitoring
Control processes are an ongoing cycle, not an isolated process improvement. It may be tempting to
remove control measures after the process appears to be in control; however continuous monitoring is the
real power of ITCV. In fact, ITCV and control charts in general are intended as a continuous method of
monitoring processes for special causes. It is unknown when a special cause will be introduced, and thus,
the process must be monitored continuously.
5.8.4 Data Driven Decision Making
Collection of ITCV data allows Amgen clinical staff to make decisions based on empirical evidence. For
example, some units in later lots began to exceed the specification limit for activation force as shown in
Figure 26 in section 5.6.1. Instead of wondering if this was due to random error, it was very clear that the
process had undergone a gradual shift. This allows Amgen to better pursue a narrow set of causal factors
and corrective actions as soon as the issue was discovered. Decision making in the presence of data is
always preferable to decision making in the absence of data.
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6 Recommendations and Future Work
6.1 Data Collection
A constraint of the program is currently the labor-intensive SATM data collection process. As a nascent
process in the clinical organization, it is expected that ITCV will be the first to slip when labor allocation
is not sufficient. It is understandable if cost concerns prevent implementation of an IT solution. It is
recommended that an analysis should be performed to determine if it is more cost effective to hire a
dedicated employee for data collection, or implement a custom IT solution to make the data readily
available. However, cost concerns should not rule the day-as Juran indicates, "higher quality costs less,
not more [16]." This investment will ensure ITCV ultimately becomes a staple tool in the clinical
manufacturing organization.
6.2 Appropriate Organizational Structure
Appropriate organizational support is essential to the survival of the ITCV implementation in the clinical
packaging group. As with the change management of any new quality process rollout in any organization,
it is important to assess the tradeoffs of personnel and equipment allocation and the expected advantage of
the outcome. A business case must be built in support of the new process rollout, and a change
management plan outlined. However, it should be analyzed as a part of the business case that additional
staff may be paid for out of reduction of quality losses [16]. Despite the fact that the clinical
manufacturing organization does not generate revenue, costs are still a concern to the broader
organization.
Beyond this implementation of ITCV, it is advantageous to dedicate some portion of the staff to clinical
process control improvement. Currently, the clinical packaging team runs at full capacity, with little time
for anything beyond day-to-day responsibilities. It is also important to ensure that the organizational
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structure of the ITCV support team includes staff with the statistical know-how to manage the recurring
activities of process control.
As mentioned earlier, it is important to define boundaries between the various quality groups in the
clinical space. The additional resource advocated in the paragraph above would need to interface with the
other quality groups to ensure that the process is clear to all involved and that drug product, medical
device, and final assembly teams all act in concert. This type of engagement also fosters teamwork and
goodwill. However, successful implementation of quality into clinical manufacturing processes will
ultimately make the precise organizational structure of quality groups less relevant-quality will be built
into the process. ITCV is part of this effort in the clinical organization.
6.3 Periodic Review
This project has reached a state where it has been identified that not all processes are in statistical
control-it is important to continue to collect data and make corrective actions until all process are in
control. Thus periodic review by a cross-functional team is important. This team should have the
authority to pursue process improvements and corrective actions, in addition to having the statistical
background to understand the data analysis.
6.4 Scope
ITCV can span as an integrated control system from raw material receipt to distribution within the clinical
manufacturing organization. This body of process data is a valuable package to hand over to commercial
manufacturing teams when a product transitions out of the clinical organization. This process data can be
used by commercial manufacturing as a platform upon which to build process excellence, instead of
starting from scratch. Due to the high stakes in the commercial manufacturing environment, quality
failures have significant costs and regulatory consequences. Ultimately, the potential for the commercial
manufacturing environment to learn from past issues in the clinical production environment may prove
more valuable to Amgen than any particular quality savings in the clinical production space.
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ITCV also has the potential to become a corporate process quality tool. As mentioned at the beginning of
this thesis, Amgen's strength lies in the workforce's "quality mindedness." However, a common program
of statistical process control tools is missing from team to team within the clinical manufacturing
organization. By standardizing methods of process improvement and process control, the "quality
mindedness" of staff can only increase. It is hoped that widespread adoption of ITCV can fill this gap and
serve as a common tool for process improvement in the clinical organization.
6.5 Conclusions
Although the process control techniques utilized in this implementation are not novel, the impact they
have had on Amgen's clinical manufacturing environment has been measurable and real. In fact, these
techniques are older than Amgen, biologics manufacturing, and the FDA itself. It is astonishing to
understand that techniques developed a century ago are still relevant in today's modem era. The original
formulation of this thesis has more than been proven by producing real time indicators of process health
illustrating the ability to use today's data to predict tomorrow's events. This ability is invaluable to any
type of manufacturer.
It is important for Amgen to understand that ITCV merely serves as a platform for process improvement.
Amgen has enjoyed significant margins and comfortable revenues in the past era, however with patent
expiry and health care cost reductions on the horizon, it is more important than ever for Amgen to focus
on the bottom line. ITCV is a perfect tool for introducing the power of systemic process improvement to
Amgen's clinical manufacturing centers. This basic implementation will hopefully serve as a launching
point for an organized campaign of quality control and process improvement to further Amgen's clinical
operation excellence.
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8 Appendix A
Table of Control Chart Constants 1171
SamP A 2  A3  d2 D3 D4 B3 B4Size=m
2 1.880 2.659 1.128 0 3.267 0 3.267
3 1.023 1.954 1.693 0 2.574 0 2.568
4 0.729 1.628 2.059 0 2.282 0 2.266
5 0.577 1.427 2.326 0 2.114 0 2.089
6 0.483 1.287 2.534 0 2.004 0.030 1.970
7 0.419 1.182 2.704 0.076 1.924 0.118 1.882
8 0.373 1.099 2.847 0.136 1.864 0.185 1.815
9 0.337 1.032 2.970 0.184 1.816 0.239 1.761
10 0.308 0.975 3.078 0.223 1.777 0.284 1.716
11 0.285 0.927 3.173 0.256 1.744 0.321 1.679
12 0.266 0.886 3.258 0.283 1.717 0.354 1.646
13 0.249 0.850 3.336 0.307 1.693 0.382 1.618
14 0.235 0.817 3.407 0.328 1.672 0.406 1.594
15 0.223 0.789 3.472 0.347 1.653 0.428 1.572
16 0.212 0.763 3.532 0.363 1.637 0.448 1.552
17 0.203 0.739 3.588 0.378 1.622 0.466 1.534
18 0.194 0.718 3.640 0.391 1.608 0.482 1.518
19 0.187 0.698 3.689 0.403 1.597 0.497 1.503
20 0.180 0.680 3.735 0.415 1.585 0.510 1.490
21 0.173 0.663 3.778 0.425 1.575 0.523 1.477
22 0.167 0.647 3.819 0.434 1.566 0.534 1.466
23 0.162 0.633 3.858 0.443 1.557 0.545 1.455
24 0.157 0.619 3.895 0.451 1.548 0.555 1.445
25 0.153 0.606 3.931 0.459 1.541 0.565 1.435
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9 Appendix B
ID APPLIES TO PROCESS EQUIPMENT CHARACTERISTICS MEASUREMENT METHODS CONTROLS
STEP
No. DEFAULT = PROCESS STEP MACHINE, PROCESS DESCRIPTION PERFORMANCE TREND DATA SOURCE DATA REVIEW PRODUCT / CONTROL OPERATOR REACTION IF OUT OF
"GENERAL" OR NAME / DEVICE, TOOL, CHARACTERISTIC EVALUATION EVALUATION (BATCH FREQUENCY FREQUENCY PROCESS LIMITS PROCESS CONTROL CONDITIONS ARE
DEFINE DESCRIPTION ETC.USED IN (DEFINES THE PARAMETER METHOD RECORD, FORM, SPEC INSTRUCTIONS ENCOUNTERED
SPECIFIC SKU, THE STEP RELEVANT ELECTRONIC (PROCEDURE
PRODUCT OR (INCL. EQUIP # CONTROLLABLE DATA CAPTURE, LL UCL #)
PACKAGING WHERE PARAMETER OF ETC.)
CONFIGURATION APPLICABLE) THE EQUIPMENT /
PROCESS)
Scratches,
Gross cosmetic D Exlue N Ad
1 Clinical Manual Operator Autoinjector defects, broken TBD: PPM Histogram Data Entry Per Batch Bach Excluded N/A N/A Excluded TBD
Autoinjector Observation Defect Autoinjector Spreadsheet
components
2 Clinical Manual Operator Glass Broken TBD: PPM Histogram Data Entry Per Batch Per Excluded N/A N/A Excluded TBDAutoinjector Observation Breakage Syringe Spreadsheet Batch
Manual Abnormal Unusual
Observation proprioceptive
3 Clinical Operator Sensation feel during TBD: PPM Histogram Data Entry Per Batch er Excluded N/A N/A ExCluded TBDAutoinjector During Press manual press Spreadsheet Batch
Stroke stroke step
Manual Dropped
Observation syringe, or
4 Clinical Operator Improper dropped TBD: PPM Histograni Data Entry Per Batch Per Excluded N/A N/A ExCluded TBDAutoinjector Handling Autoinjector Spreadsheet Batch
containing
syringe
Manual Misalignment Misalignment Conduct investigation
5 Clinical Observation Operator During during first TBD: PPM Histogram Data Entry Per Batch Ba Excluded N/A N/A Excluded and escalate to ProductAutoinjector Assembly press step Spreads Batch Team
(Rear Assy)
Manual Misalignment Misalignment Conduct investigation
6 Clinical Observation Operator During during second TBD Histogram Data Entry Per Batch Ba Excluded N/A N/A Excluded and escalate to ProductAutoinjector Assembly press step Spreadsheet Team
(Front Assy)
ID APPLIES TO PROCESS EQUIPMENT CHARACTERISTICS MEASUREMENT METHODS CONTROLS
STEP
No. DEFAULT PROCESS STEP MACHINE, PROCESS DESCRIPTION PERFORMANCE TREND DATA SOURCE DATA REVIEW PRODUCT / CONTROL OPERATOR REACTION IF OUT OF
"GENERAL"OR NAME/ DEVICE, TOOL, CHARACTERISTIC EVALUATION EVALUATION (BATCH FREQUENCY FREQUENCY PROCESS LIMITS PROCESS CONTROL CONDITIONS ARE
DEFINE DESCRIPTION ETC.USED IN (DEFINES THE PARAMETER METHOD RECORD, FORM, SPEC INSTRUCTIONS ENCOUNTERED
SPECIFIC SKU, THE STEP RELEVANT ELECTRONIC (PROCEDURE
PRODUCT OR (INCL. EQUIP # CONTROLLABLE DATA CAPTURE, LCL UCL #)
PACKAGING WHERE PARAMETER OF ETC.)
CONFIGURATION APPLICABLE) THE EQUIPMENT /
PROCESS)
Manual Syringe falls
Observation Syringe off press Conduct investigation
7 Clinical Operator Barrel because TBD Histogram Data Entry Per Batch Per Excluded N/A N/A Excluded and escalate to ProductAutoinjector Dimension syringe Spreadsheet Batch Team
too Large dimension is
not adequate
Semi Per
Clinical Functional utomatic Dlivrm e delivered Control SATM- Each Excluded 
Conduct investigation
8 Cltinicl Functional Testing Dliverable) dliere Excluded Conto Manual Data Batch Batch TBD TBD Excluded and escalate to Product
Autoinjector Testing Machine Volut(DLV) during Chart Maul Portion Team
(SATM) activation
Semi Per
Automatic Control SATM- Each Excluded Conduct investigation
9 Clinical Functional Testing Injection Length of Excluded Cot Manual Data Batch Batch TBD TBD Excluded and escalate to ProductAutoinjector Testing Machine Time (IT) delivery time Chart Capture Portion Team
(SATM)
Semi Per
Automatic Ctl SATM- Each Excluded Conduct investigation
10 Clinical Functional Testing Activation Force required Excluded ont Manual Data Batch Batch TBD TBD Excluded and escalate to ProductAutoinjector Testing Machine Force (ATF) to activate unit Capture Portion Team
(SATM)
Per
Clinical Functional Needle Needle Length of Control Laptop- Each Excluded 
Conduct investigation
11 Tesinicl Funtinag Extension Extension Needle Excluded Chart Manual Data Batch Batch TBD TBD Excluded and escalate to ProductAutoinjector Gauge (IJD) Extension Capture Portion Team
Ratio batch Conduct investigation
12 Clinical Yield Batch size to Reject Rate % Accepted Run Chart EBR Per Batch Per Excluded N/A N/A Excluded and escalate to ProductAutoinjector Record components Batch Team
used
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10 Appendix C
P chart of defects: control limits are distracting due to varying autoinjector build size.
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11 Appendix D
ATF Normality Check
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IJT (Active) Normality Check
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DLV Normality Check
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IJT (Placebo) Normality Check
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12 Appendix E
IJT Placebo Analysis
E
U
0
U
Sample
4.
3.
m 3.
c
E
-2U
0
C0
a
2.
2.
1.
1.
0.
0.
0o e n Ln
,-4 - r rj N e
Column 13
77
0-
5-
0-5-
5- UCL
.Avg
LCL
5 -
0
4.
4.
4.
4.
4.
3.
3.
3.
co4
Column 13
78
E
U
0
8
6-
4 -
4 UCL
2 - \
0 - _ _Avg=
8 - \
6 I LCL
____________
A.
